Ebola may soon be a “preventable and treatable” disease after a trial of two drugs showed significantly improved survival rates, scientists have said.
Four drugs were trialled on patients in the Democratic Republic of Congo, where there is a major outbreak of the virus.
Two of those, named REGN-EB3 and mAb114, were more effective in treating the disease, the study found.
The drugs will now be used to treat Ebola patients in DR Congo, according to health officials.
The US National Institute of Allergy and Infectious Diseases (NIAID), which co-sponsored the trial, said the results are “very good news” for the fight against Ebola.
The drugs work by attacking the Ebola virus with antibodies, neutralising its impact on human cells.
They were developed using antibodies harvested from survivors of Ebola, which has killed more than 1,800 people in DR Congo in the past year.
Two other treatments, called ZMapp and Remdesivir, have been dropped from trials as they were found to be less effective.
Of the patients given the two more effective drugs, 29% on REGN-EB3 and 34% on mAb114 died, NIAID said.
In contrast, 49% on ZMapp and 53% on Remdesivir died in the study, the agency said.
The survival rate among patients with low levels of the virus in their blood was as high as 94% when they were given REGN-EB3, and 89% when on mAb114, the agency said.
The World Health Organization (WHO) co-ordinated the trial, which began in November last year.
Hailing the success of the study, Jeremy Farrar, director of the Wellcome Trust global health charity, said the treatments would “undoubtedly save lives”.
The findings, Mr Farrar said, indicate scientists are getting closer to turning Ebola into a “preventable and treatable” disease.
“We won’t ever get rid of Ebola but we should be able to stop these outbreaks from turning into major national and regional epidemics,” he added.
The current outbreak in eastern DR Congo began in August last year and is the biggest of the 10 to hit the country since 1976, when the virus was first discovered.
But it is dwarfed by the West African epidemic of 2014-16, which affected 28,616 people mainly in Guinea, Liberia and Sierra Leone. About 11,310 people died in what was the largest outbreak of the virus ever recorded.